Interaction Checker

Apps

Download from the AppStore

Download from Google Play

Interaction Checker
About Us
Mission Statement Meet the Team Steering Committee
Interaction Checkers
Interaction Checker Español Checker Português Checker Interaction Checker Lite View All Checker
Prescribing Resources Videos Site News
Contact Us
Feedback Form Suggest a Drug
Support Us
Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Do Not Coadminister

Doravirine (DOR)

Dolutegravir/Rilpivirine (DTG/RPV)

Quality of Evidence: Very Low

Summary:

Juluca (dolutegravir/rilpivirine) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. Furthermore, doravirine should not be administered with products containing another NNRTI (i.e. rilpivirine).

Description:

Juluca should not be administered with other antiretroviral medicinal products for the treatment of HIV.
Juluca Summary of Product Characteristics, ViiV Healthcare Ltd, May 2018.

Because Juluca is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended.
Juluca US Prescribing Information, ViiV Healthcare Ltd, September 2018.

View all available interactions with Doravirine (DOR) by clicking here.

SPONSORS
EDITORIAL SPONSORS
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
healthline-best-HIV-and-AIDS-apps-of-2019
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016
Cookie Policy Privacy Statement Terms & Conditions

Copyright © 2025 The University of Liverpool. All rights reserved.